| Today’s Big NewsSep 10, 2024 |
| By Conor Hale The tech giant plans to add sleep apnea detection to its Apple Watch as well as bring long-anticipated over-the-counter hearing aid tech to its AirPods. |
|
|
|
By James Waldron The recent decision to merge Genentech’s two cancer departments was made for “scientific reasons,” according to executives. |
By Fraiser Kansteiner Late Monday, the U.S. House of Representatives voted 306-81 in favor of the BIOSECURE Act, which was introduced in January and seeks to halt federal contracts with five named Chinese life-sci companies: WuXi AppTec, WuXi Biologics, BGI Group, MGI and Complete Genomics. |
By Darren Incorvaia Carisma Therapeutics has been working for years to develop cell therapies using macrophages, immune cells that are better at attacking solid tumors than the T cells that currently dominate the industry. In a partnership with Moderna, now expanded to two undisclosed autoimmune targets, the biotech hopes to seriously simplify cell therapy by bypassing the need to culture patient cells out of the body. |
|
Still Time to Shine! Submission deadline for the Fierce Life Sciences Innovation Awards have been extended to September 12. Click to submit your entry and learn more about what winner's will receive.
|
|
By Nick Paul Taylor Physicians consider more than what a drug does when making prescribing decisions. They also look at who is behind the therapy. That is the conclusion of a WE Communications survey that found physicians are influenced by disease-specific leadership and corporate reputation when choosing which drug to use. |
By Nick Paul Taylor Viridian Therapeutics’ phase 3 thyroid eye disease clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to question whether the biotech has done enough to differentiate its asset and unseat the incumbent. |
By Conor Hale Au revoir, Abiomed. Goodbye, DePuy. Bon voyage, Biosense. So long, Cerenovus. Adios, Ethicon. |
By Zoey Becker The city scored its own deal after opting not to join in on Teva's $4.25 billion national opioid settlement. |
By Zoey Becker Gilead is paying $35 million to access Genesis' tech. The deal covers three targets, with an option for more down the line. |
By Gabrielle Masson On the heels of disappointing low-dose data results, Zealand Pharma is back with separate findings for its GLP-1/GLP-2 receptor dual agonist that have emboldened the biotech to push the candidate into phase 2b development. |
By Ben Adams AbbVie’s migraine drug Ubrelvy (ubrogepant) is slated to be the top-selling drug in the migraine space in 2033 across the seven bigger pharma markets as total spend across those countries are set to rake in $16.4 billion. |
By Joseph Keenan Two Japanese drugmakers and another in India were hit with Form 483s from the FDA following inspections that uncovered issues ranging from a lack of sanitary procedures to improper data collection and monitoring. |
Fierce podcastsDon’t miss an episode |
| In this week's episode of "The Top Line," we’re looking at what goes into manufacturing and supply of flu vaccines. |
|
|---|
|
|
|
Bringing new oncology therapies to market is challenging, but novel, safer treatments are needed. Download the new QPS Oncology white paper to learn more about oncology clinical trials, challenges and solutions.
|
|
| WhitepaperFacing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
| WhitepaperWe interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
| WhitepaperFinding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
